N@N

SciClone Pharmaceuticals to Present at Three Investor Conferences in June

_{//health-fitness.news-articles.net/content/2010/ .. esent-at-three-investor-conferences-in-june.html}
^{Published in Health and Fitness on Thursday, June 3rd 2010 at 13:20 GMT by Market Wire}  

FOSTER CITY, CA--(Marketwire - June 3, 2010) - SciClone Pharmaceuticals, Inc. (NASDAQ: [ SCLN ]) today announced that it will present at three upcoming investor conferences: Jefferies 2010 Global Life Sciences Conference, Needham Annual Healthcare Conference, and ThinkEquity Mid-Year Check up on Healthcare Conference. SciClone's executives will present a corporate overview and business update at each conference.

Jefferies Global Life Sciences Conference
Wednesday, June 9; 10:00 am ET
New York City, NY
Presenter: Gary Titus, Senior Vice President and CFO

Needham Annual Healthcare Conference
Thursday, June 10; 1:20 pm ET
New York City, NY
Presenter: Gary Titus, Senior Vice President and CFO

ThinkEquity Mid-Year Check up on Healthcare Conference
Wednesday, June 16; 3:00 pm ET
New York City, NY
Presenter: Friedhelm Blobel, PhD, President and CEO

To access the live audio webcasts of the presentations, please log on through a link located in the Investor Relations section of SciClone's website at [ www.sciclone.com ].

About SciClone
SciClone Pharmaceuticals (NASDAQ: [ SCLN ]) is a profit-focused, global specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and overall expense management. ZADAXIN^® (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin, in clinical studies as an enhancer of vaccines; SCV-07 in a phase 2 trial for the delay to onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; and SCV-07 in a phase 2 trial for the treatment of HCV. SciClone has exclusive commercialization and distribution rights to DC Bead™ in China, where the product is under regulatory review. The Company also has exclusive commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm™ in China, including Hong Kong and Macau, and Vietnam, for which it will seek regulatory approval. For additional information, please visit [ www.sciclone.com ].